SGLT2 inhibitors may potentially assist BP goal achievement in people with type 2 diabetes and hypertension within 3–5 mm Hg which varies slightly by specific SGLT2 inhibitor but does not reach the desired levels achieved by primary antihypertensive agents [48]. Here, SLC5A2 is linked to type 2 diabetes mellitus.